Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 174581, 5 pages
http://dx.doi.org/10.1155/2014/174581
Research Article

Beta-Thalassaemia Intermedia: Evaluation of Endocrine and Bone Complications

1Rare Diseases Center, Department of Medicine and Medical Specialities, Ca’ Granda Foundation IRCCS Ospedale Maggiore Policlinico, 20122 Milan, Italy
2Department of Clinical Sciences and Community Health, University of Milan, Via F. Sforza, 20122 Milan, Italy
3Nuclear Medicine, Bone Metabolic Unit, Ca’ Granda Foundation IRCCS Ospedale Maggiore Policlinico, 20122 Milan, Italy

Received 4 April 2014; Revised 11 June 2014; Accepted 16 June 2014; Published 7 July 2014

Academic Editor: Paolo Ricchi

Copyright © 2014 M. Baldini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. M. Musallam, S. Rivella, E. Vichinsky, and E. A. Rachmilewitz, “Non-transfusion-dependent thalassemias,” Haematologica, vol. 98, no. 6, pp. 833–844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. Weatherall, “The definition and epidemiology of non-transfusion-dependent thalassemia,” Blood Reviews, vol. 26, supplement 1, pp. S3–S6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Weatherall, “Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias,” Nature Reviews Genetics, vol. 2, no. 4, pp. 245–255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. N. C. Andrews, “Iron homeostasis: insights from genetics and animal models,” Nature Reviews Genetics, vol. 1, no. 3, pp. 208–217, 2000. View at Google Scholar · View at Scopus
  5. B. Wonke, “Bone disease in beta-thalassaemia major,” British Journal of Haematology, vol. 103, no. 4, pp. 897–901, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Perrotta, M. D. Cappellini, F. Bertoldo et al., “Osteoporosis in β thalassaemia major patients: analysis of the genetic background,” British Journal of Haematology, vol. 111, pp. 461–466, 2000. View at Google Scholar
  7. R. D. Pollak, E. Rachmilewitz, A. Blumenfeld, M. Idelson, and A. W. Goldfarb, “Bone mineral metabolism in adults with β-thalassaemia major and intermedia,” British Journal of Haematology, vol. 111, no. 3, pp. 902–907, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. D. Cappellini, A. Cohen, A. Eleftheriou, A. Piga, J. Porter, and A. Taher, Guidelines for the Clinical Management of Thalassaemia, Revised, Thalassaemia International Federation, Nicosia, Cyprus, 2nd edition, 2008.
  9. A. T. Taher, K. M. Musallam, V. Viprakasit, J. B. Porter, and M. D. Cappellini, “Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo,” Blood Cells, Molecules & Diseases, vol. 52, no. 2-3, pp. 88–90, 2014. View at Google Scholar
  10. N. F. Olivieri, G. M. Muraca, A. O'Donnell, A. Premawardhena, C. Fisher, and D. J. Weatherall, “Studies in haemoglobin E beta-thalassaemia,” British Journal of Haematology, vol. 141, no. 3, pp. 388–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Lal, M. L. Goldrich, D. A. Haines, M. Azimi, S. T. Singer, and E. P. Vichinsky, “Heterogeneity of hemoglobin H disease in childhood,” The New England Journal of Medicine, vol. 364, no. 8, pp. 710–718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Sripichai, W. Makarasara, T. Munkongdee et al., “A scoring system for the classification of β-thalassemia/Hb E disease severity,” American Journal of Hematology, vol. 83, no. 6, pp. 482–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. T. Taher, K. M. Musallam, M. Karimi et al., “Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study,” Blood, vol. 115, no. 10, pp. 1886–1892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. Musallam, M. D. Cappellini, J. C. Wood et al., “Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia,” Haematologica, vol. 96, no. 11, pp. 1605–1612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. M. Musallam, M. D. Cappellini, and A. T. Taher, “Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia,” Blood Cells, Molecules, and Diseases, vol. 51, no. 1, pp. 35–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Kurtoglu, E. Kurtoglu, and A. K. Temizkan, “Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia,” Endokrynologia Polska, vol. 63, no. 4, pp. 260–263, 2012. View at Google Scholar · View at Scopus
  17. A. T. Taher, K. M. Musallam, A. El-Beshlawy et al., “Age-related complications in treatment-naïve patients with thalassaemia intermedia,” British Journal of Haematology, vol. 150, no. 4, pp. 486–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Haidar, K. M. Musallam, and A. T. Taher, “Bone disease and skeletal complications in patients with β thalassemia major,” Bone, vol. 48, no. 3, pp. 425–432, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. K. M. Musallam, A. T. Taher, L. Duca, C. Cesaretti, R. Halawi, and M. D. Cappellini, “Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with beta thalassemia intermedia,” Blood Cells, Molecules, and Diseases, vol. 47, no. 4, pp. 232–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Rivella, “The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia,” Blood Reviews, vol. 26, no. 1, pp. S12–S15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. K. M. Musallam, V. G. Sankaran, M. D. Cappellini, L. Duca, D. G. Nathan, and A. T. Taher, “Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia,” Blood, vol. 119, no. 2, pp. 364–367, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Cao, P. Moi, and R. Galanello, “Recent advances in beta-thalassemias,” Pediatric Reports, vol. 3, no. 2, article E17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Taher, H. Isma'eel, and M. D. Cappellini, “Thalassemia intermedia: revisited,” Blood Cells, Molecules, and Diseases, vol. 37, no. 1, pp. 12–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Martinez-Jabaloyas, “Hipogonadism. Global epidemiology and transversal relationships,” Archivos Españoles de Urología, vol. 66, no. 7, pp. 632–638, 2013. View at Google Scholar
  25. J. P. Almandoz and H. Gharib, “Hypothyroidism: etiology, diagnosis, and management,” Medical Clinics of North America, vol. 96, no. 2, pp. 203–221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Sarwar, P. Gao, S. R. Seshasai et al., “Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies,” The Lancet, vol. 375, no. 9733, pp. 2215–2222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Haidar, H. Mhaidli, and A. T. Taher, “Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia,” European Spine Journal, vol. 19, no. 6, pp. 871–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Aessopos, M. Kati, and J. Meletis, “Thalassemia intermedia today: should patients regularly receive transfusions?” Transfusion, vol. 47, no. 5, pp. 792–800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. G. Vogiatzi, K. A. Autio, J. E. Mait, R. Schneider, M. Lesser, and P. J. Giardina, “Low bone mineral density in adolescents with β-thalassemia,” Annals of the New York Academy of Sciences, vol. 1054, pp. 462–466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Vieth, “Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults,” Journal of Steroid Biochemistry and Molecular Biology, vol. 89-90, pp. 575–579, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. E. B. Fung, C. Aguilar, I. Micaily, D. Haines, and A. Lal, “Treatment of vitamin D deficiency in transfusion-dependent thalassemia,” The American Journal of Hematology, vol. 86, no. 10, pp. 871–873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Soliman, V. de Sanctis, and M. Yassin, “Vitamin D status in thalassemia major: an update,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 5, no. 1, Article ID e2013057, 2013. View at Google Scholar
  33. M. Baldini, S. Forti, A. Marcon et al., “Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major,” Annals of Hematology, vol. 89, no. 12, pp. 1207–1213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. T. Taher, K. M. Musallam, and A. Inati, “Iron overload: consequences, assessment, and monitoring,” Hemoglobin, vol. 33, supplement 1, pp. S46–S57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. H. Nassar, I. M. Usta, J. B. Rechdan, S. Koussa, A. Inati, and A. T. Taher, “Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns,” The American Journal of Hematology, vol. 81, no. 7, pp. 499–502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Papadimas, D. G. Goulis, E. Mandala et al., “Beta-thalassemia and gonadal axis: a cross-sectional, clinical study in a Greek population,” Hormones, vol. 1, pp. 179–187, 2002. View at Google Scholar
  37. N. Skordis, S. Christou, M. Koliou, N. Pavlides, and M. Angastiniotis, “Fertility in female patients with thalassemia,” Journal of Pediatric Endocrinology and Metabolism, vol. 11, supplement 3, pp. 935–943, 1998. View at Google Scholar · View at Scopus
  38. M. Bagnasco, I. Bossert, and G. Pesce, “Stress and autoimmune thyroid diseases,” NeuroImmunoModulation, vol. 13, no. 5-6, pp. 309–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. T. Taher, J. B. Porter, V. Viprakasit et al., “Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study,” Annals of Hematology, vol. 92, pp. 1485–1493, 2013. View at Publisher · View at Google Scholar · View at Scopus